News

The European Commission (EC) has approved UCB’s Cimzia, in combination with MTX, for the treatment of moderate to severe active RA in adult patients inadequately responsive to disease-modifying

GlaxoSmithKline (GSK) has provided an update on orders received for its pandemic (H1N1) adjuvanted vaccine. Reportedly, on 4th August, GSK confirmed that it had contracts in place to

Patheon has signed an agreement with Zycus to deploy the latter’s iSource software to accelerate the company’s return on investment and standardise its tendering process. Jonathan Arnold, VP

Illumina has launched IlluminaCompute, a fully-integrated computing solution for its Genome Analyzer sequencing platform. The new product conserves IT resources by providing centralized high-performance computational and storage infrastructure,

Nutra Pharma has completed the first production run of Cobroxin and has successfully released it for final distribution. The company expects Cobroxin to be available for sale as

Enzon Pharmaceuticals has reported that the FDA Oncologic Drug Advisory Committee has voted in favor of approval of Pegintron as a treatment in addition to surgery in patients

Kureha Corporation and Mitsubishi Tanabe Pharma have entered into an agreement, under which Kureha shall grant Mitsubishi Tanabe a license to market chronic renal failure drug Kremezin in

AstraZeneca has revealed the results of phase IIIb study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy. The study revealed that treatment with

Peregrine Pharmaceuticals has reported additional positive results from its phase II trial. The study evaluated bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung